Alland arrives at Cardiff Oncology with an extensive background in the pharmaceutical sector. Her resume includes previous stints as chief medical officer at PMV Pharma, Affimed, and Tarveda Therapeutics. Beyond these executive roles, she has held significant leadership positions at major industry players, specifically Novartis, Bristol Myers Squibb, and AstraZeneca. The company has not yet provided further details regarding the specific circumstances surrounding Sidhu’s exit.
Cardiff Oncology Taps Leila Alland as Interim Medical Chief
Cardiff Oncology has appointed Leila Alland as its interim chief medical officer following the sudden departure of Roger Sidhu. The biotechnology firm confirmed the leadership transition on Tuesday, signaling a shift in its clinical development oversight as it navigates its current pipeline of oncology treatments.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!